









市場行情
/
股票
/
nasdaq-abeo
/

Abeona Therapeutics Inc

ABEO

5.440USD

+0.330+6.46%

收盤 12/22, 16:00（美東）報價延遲15分鐘

285.06M總市值

3.36本益比TTM



Abeona Therapeutics Inc

5.440

+0.330+6.46%

概覽公司財務分析

概覽

公司

財務

分析

關於 Abeona Therapeutics Inc 公司

Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).

Abeona Therapeutics Inc簡介



公司代碼ABEO

公司名稱Abeona Therapeutics Inc

上市日期Sep 19, 1980

CEOSeshadri (Vishwas)

員工數量136

證券類型Ordinary Share

年結日Sep 19

公司地址6555 Carnegie Ave, 4th Floor

城市CLEVELAND

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編44103

電話16468134701

網址https://abeonatherapeutics.com/

公司代碼ABEO

上市日期Sep 19, 1980

CEOSeshadri (Vishwas)

Abeona Therapeutics Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Vishwas (Vish) Seshadri, Ph.D.

President, Chief Executive Officer, Director

1.19M

-0.02%

Mr. Michael Amoroso

Chairman of the Board

180.47K

Dr. Leila Alland, M.D.

Independent Director

154.37K

Mr. Donald A. Wuchterl

Independent Director

145.44K

-3.44%

Ms. Christine Berni Silverstein

Independent Director

120.48K

-9.80%

Mr. Mark J. Alvino

Independent Director

62.34K

-19.39%

Dr. Bernhardt G. Zeiher, M.D.

Independent Director

47.15K

Dr. Eric Crombez, M.D.

Independent Director

Mr. Joseph Vazzano, CPA

Chief Financial Officer

Ms. Faith L. Charles, J.D.

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Dr. Vishwas (Vish) Seshadri, Ph.D.

President, Chief Executive Officer, Director

1.19M

-0.02%

Mr. Michael Amoroso

Chairman of the Board

180.47K

Dr. Leila Alland, M.D.

Independent Director

154.37K

Mr. Donald A. Wuchterl

Independent Director

145.44K

-3.44%

Ms. Christine Berni Silverstein

Independent Director

120.48K

-9.80%

Mr. Mark J. Alvino

Independent Director

62.34K

-19.39%

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 12月4日週四

持股股東

股東類型

持股股東

佔比

Nantahala Capital Management, LLC

8.42%

Adage Capital Management, L.P.

5.62%

BlackRock Institutional Trust Company, N.A.

5.26%

James Russell Revocable Trust

5.02%

Suvretta Capital Management, LLC

4.94%

其他

70.74%

持股股東

佔比

Nantahala Capital Management, LLC

8.42%

Adage Capital Management, L.P.

5.62%

BlackRock Institutional Trust Company, N.A.

5.26%

James Russell Revocable Trust

5.02%

Suvretta Capital Management, LLC

4.94%

其他

70.74%

股東類型

持股股東

佔比

Hedge Fund

29.19%

Investment Advisor

18.72%

Investment Advisor/Hedge Fund

9.68%

Individual Investor

5.33%

Corporation

5.02%

Research Firm

4.84%

Venture Capital

4.23%

Bank and Trust

0.09%

Pension Fund

0.06%

其他

22.85%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

204

36.22M

79.02%

-9.77K

2025Q3

209

38.81M

82.28%

+643.18K

2025Q2

192

38.19M

68.92%

+5.47M

2025Q1

135

32.70M

74.05%

-3.55M

2024Q4

131

33.67M

75.84%

+1.89M

2024Q3

124

31.78M

82.54%

-3.17M

2024Q2

126

34.94M

52.06%

+14.17M

2024Q1

122

17.08M

56.78%

+1.44M

2023Q4

112

16.39M

53.86%

+3.77M

2023Q3

118

12.21M

54.85%

+1.48M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Nantahala Capital Management, LLC

4.56M

8.9%

+195.00K

+4.46%

Sep 30, 2025

Adage Capital Management, L.P.

3.07M

5.99%

+381.36K

+14.17%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

2.72M

5.3%

+2.24M

+475.57%

Jun 30, 2025

Suvretta Capital Management, LLC

2.68M

5.22%

-1.01M

-27.39%

Jun 30, 2025

The Vanguard Group, Inc.

2.51M

4.89%

+486.84K

+24.10%

Jun 30, 2025

Vivo Capital, LLC

1.84M

3.59%

Jun 30, 2025

Western Standard, LLC

2.09M

4.08%

-189.60K

-8.31%

Jun 30, 2025

Seshadri (Vishwas)

1.19M

2.32%

-44.27K

-3.59%

Sep 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Simplify Propel Opportunities ETF

3.97%

iShares Micro-Cap ETF

0.04%

Proshares Ultra Russell 2000

0.01%

ProShares Hedge Replication ETF

0.01%

iShares Russell 2000 Growth ETF

0.01%

ProShares UltraPro Russell2000

0.01%

iShares Russell 2000 ETF

0.01%

Global X Russell 2000 ETF

0.01%

Vanguard US Momentum Factor ETF

iShares Core S&P Total U.S. Stock Market ETF

Simplify Propel Opportunities ETF

佔比3.97%

iShares Micro-Cap ETF

佔比0.04%

Proshares Ultra Russell 2000

佔比0.01%

ProShares Hedge Replication ETF

佔比0.01%

iShares Russell 2000 Growth ETF

佔比0.01%

ProShares UltraPro Russell2000

佔比0.01%

iShares Russell 2000 ETF

佔比0.01%

Global X Russell 2000 ETF

佔比0.01%

Vanguard US Momentum Factor ETF

佔比0%

iShares Core S&P Total U.S. Stock Market ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

Jul 01, 2022

Merger

25→1

Jul 01, 2022

Merger

25→1

Jul 01, 2022

Merger

25→1

Jul 01, 2022

Merger

25→1

公告日期

類型

比率

Jul 01, 2022

Merger

25→1

Jul 01, 2022

Merger

25→1

Jul 01, 2022

Merger

25→1

Jul 01, 2022

Merger

25→1

常見問題

Abeona Therapeutics Inc的前五大股東是誰？



Abeona Therapeutics Inc的前五大股東如下：
Nantahala Capital Management, LLC
持有股份：4.56M
佔總股份比例：8.90%。
Adage Capital Management, L.P.
持有股份：3.07M
佔總股份比例：5.99%。
BlackRock Institutional Trust Company, N.A.
持有股份：2.72M
佔總股份比例：5.30%。
Suvretta Capital Management, LLC
持有股份：2.68M
佔總股份比例：5.22%。
The Vanguard Group, Inc.
持有股份：2.51M
佔總股份比例：4.89%。